Anxiety, Stress
Conditions
Brief summary
A randomized, double-blinded, placebo-controlled study assessing the impact of health and wellness products on feeling of anxiety, stress, and other health outcomes
Detailed description
This is a randomized, double-blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States. Eligible participants will (1) endorse a desire for less anxiety or stress, (2) indicate an interest in taking a health and wellness product to potentially help their feelings of anxiety or stress, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study. Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded. Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.
Interventions
DIETARY_SUPPLEMENTCalm Active Study Product 1.1 Usage
Participants will use their Radicle Calm Active Study Product 1.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTCalm Active Study Product 1.2 Usage
Participants will use their Radicle Calm Active Study Product 1.2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTCalm Active Study Product 1.3 Usage
Participants will use their Radicle Calm Active Study Product 1.3 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 1
Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 2
Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTCalm Active Study Product 2.1 Usage
Participants will use their Radicle Calm Active Study Product 2.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 3
Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTCalm Active Study Product 3.1 Usage
Participants will use their Radicle Calm Active Study Product 3.1 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTPlacebo Control Form 4
Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.
DIETARY_SUPPLEMENTCalm Active Study Product 4.1 Usage
Participants will use their Radicle Calm Active Study Product 4.1 as directed for a period of 6 weeks.
Sponsors
Radicle Science
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
The investigator is blinded to the participants' study product assignment. Participants are blinded to the study product they are assigned.
Intervention model description
Participants will be stratified based on gender at birth then randomized to one of the study arms
Eligibility
Sex/Gender
ALL
Age
21 Years to 105 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities * Resides in the United States * Endorses fewer feelings of anxiety or stress as a primary desire * Selects feelings of anxiety or stress, looking to improve their feelings of anxiety or stress, and/or reduce reliance on medications as a reason for their interest in taking a health and wellness product * Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
Exclusion criteria
* Reports being pregnant, trying to become pregnant, or breastfeeding * Unable to provide a valid US shipping address * The calculated validated health survey (PRO) measurement result is less than mild severity/impairment * Reports a diagnosis of liver or kidney disease * Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day) * Unable to read and understand English * Reports current enrollment in a clinical trial * Lack of reliable daily access to the internet * Reports current or recent (within 3 months) use of chemotherapy, immunotherapy, or oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection * Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied: anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, or MAOIs (monoamine oxidase inhibitors) * Reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: NYHA (New York Heart Association) Class III or IV congestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in feelings of anxiety | 6 weeks | Mean difference in feelings of anxiety score as assessed by Patient Reported Outcome Measurement System (PROMIS) Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in cognitive function | 6 weeks | Mean difference in cognitive function score as assessed by PROMIS Cognition Function 4A (scale 4-20; where lower scores correspond to poorer cognitive function) |
| Change in sleep | 6 weeks | Mean difference in sleep score as assessed by PROMIS Sleep Disturbance 4A (scale 4-20; where lower scores correspond to better sleep quality/less sleep disturbance) |
| Change in stress | 6 weeks | Mean difference in stress score as assessed by National Institutes of Health (NIH) Toolbox Perceived Stress Survey (scale 10-50; where lower scores correspond to less stress) |
| Change in libido | 6 weeks | Mean difference in libido score as assessed by PROMIS Sexual Interest 2.0 (scale 2-10; where lower scores correspond to less interest in sexual activity) |
| Minimal clinically important difference (MCID) in feelings of anxiety | 6 weeks | Likelihood of achieving a MCID in sleep disturbance, as measured by PROMIS Anxiety 8A (scale 8-40; where lower scores correspond to less feelings of anxiety) |
| Change in mood (emotional distress) | 6 weeks | Mean difference in mood score as assessed by PROMIS Emotional Distress-Depression 4A (scale 4-20; where lower scores correspond to lower levels of emotional distress) |
Countries
United States
Outcome results
None listed